FILING ANALYSIS · FRIDAY, NOVEMBER 6
Protara Therapeutics, Inc. TARA — 8-K: Results of Operations and Financial Condition
neutral
Protara Therapeutics announced financial results for Q3 2026 and provided a business update, including expected completion of enrollment for the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial and a purchase agreement for TARA-002 manufacturing-related assets, with cash and investments of approximately $143 million as of September 30, 2026
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →